Inaugural Emerging Scholars Symposium scheduled for April 30

 

 One of the most innovative of the “high-risk, high-reward” grant programs at the A. Alfred Taubman Medical Research Institute is the Emerging Scholars Program, which often is referred to as the “jewel in the crown” of the institute’s initiatives.

Not only do these grants support the current work of the best and brightest of the early-career clinician-scientists on the U-M Medical School faculty, they achieve the crucial goal of keeping our health science research pipeline full.

Talented, passionate physician-researchers with the vision and energy to solve complex medical puzzles should not be deterred for lack of funds. Thanks to the contributions of the generous donors who have pledged three years of funding for each scientist, the institute now is jump-starting the careers of 11 Emerging Scholars who combine their patient practice with cutting-edge research into cancer, neurological disorders and other complex diseases.  

And now, the first-ever Emerging Scholars Symposium will present a morning of science featuring presentations by six of our remarkable Emerging Scholars, who are seeking new discoveries and treatments in fields ranging from ovarian cancer to major depression.

The Emerging Scholars Symposium will run from 10 a.m. to noon in the Kahn Auditorium of the A. Alfred Taubman Biomedical Science Research Building at U-M. For a map to the AAT-BSRB, click here.

The symposium is open to the entire University of Michigan community and to the general public.   No registration is required.

To view a short video about the Emerging Scholars program, click here.

The presenting Emerging Scholars and their talks are:

 

 Ron Buckanovich , M.D., Ph.D. “Developing Cancer Stem Cell Targeted Therapy to Prevent Disease Recurrence”

 

 Sung Won Choi, M.D. “Histone deacetylase inhibition in graft-vs.-host disease”

 

 Erika Newman , M.D. “Targeting Nonhomologous End-joining in Therapy-resistant Neuroblastoma”

 

 Brian Mickey, M.D., Ph.D. “Biomarker Discovery for Refractory Mood Disorders”

 

 Parag Patil, M.D., Ph.D. “Treating Movement Disorders and Depression with Deep-Brain Stimulation”

 

 Srijan Sen, M.D., Ph.D. “Medical Internship as a Model to Identify Biological Predictors of Depression Under Stress”

 

 

 


Help Us Make A Difference. Make A Donation That Could Save Lives.

Make A Gift

Connect/
Share/
follow/

Follow Us / Friend Us

Discovery-driven research that matters

phallodin

Taubman Scholar Dr. Charles Burant tests promising diabetes drug

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

Read more

Taubman Institute leaders make the case for more doctor-scientist funding

 

The prestigious "Academic Medicine" journal has just published a new article authored by Taubman Institute senior management and Detroit-area attorney Scott Roberts.

The article explores the problematic gap between bench research and clinical application of new treatments or cures. 

Read more


Help Us Make A Difference. Make A Gift.

Leaders from the realms of business, academia and the community help to refine the Taubman Institute's vision, to monitor progress and to provide support, advice and counsel.

Meet the Leadership Advisory Board

Meet the Scientific Advisory Board

About Taubman Institute Video

In this video feature, Taubman Scholars explain why funding for high-risk research is so important to their work and to the discovery of promising cures and treatments.  

 

Stem cell surgery targets ALS Video

Patients glean hope from trial’s progress but wish it were faster

 

video-emerging-scholars-programDonors pitch in to keep brilliant science minds at U-M Video

Emerging Scholars program connects promising M.D.-researchers with philanthropists